LEADER 01518nam  2200409 a 450 
001 9910702015503321
005 20120904154419.0
035   $a(CKB)5470000002423977
035   $a(OCoLC)809108726
035   $a(EXLCZ)995470000002423977
100   $a20120904d2010      ua             0
101 0 $aspa
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aSi?ndrome de Tourette$b[electronic resource] /$f[preparado por: Office of Communications and Public Liaison, National Institute of Neurological Disorders and Stroke]
205   $aRevisado Feb. 10, 2010.
210  1$aBethesda, MD :$cNational Institute of Neurological Disorders and Stroke, National Institutes of Health,$d[2010]
215   $a1 online resource
225 1 $aPublicacio?n de NIH ;$v06-2163s
300   $aTitle from caption (viewed Sept. 4, 2012).
300   $a"Septiembre 2006."
606   $aTourette syndrome
606   $aTourette syndrome$vPopular works
606   $aTourette syndrome$xTreatment$vPopular works
615  0$aTourette syndrome.
615  0$aTourette syndrome
615  0$aTourette syndrome$xTreatment
712 02$aNational Institute of Neurological Disorders and Stroke (U.S.).$bOffice of Communications and Public Liaison.
712 02$aNational Institutes of Health (U.S.)
801  0$bGPO
801  1$bGPO
906   $aBOOK
912   $a9910702015503321
996   $aSi?ndrome de Tourette$93127611
997   $aUNINA